3 Day Blinds Inc.

New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met[R] (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone.
Heart Disease Weekly; 11/22/2009; 2613 words; ...Pharmaceuticals North America, Inc. "We are pleased to see that...dizziness and insomnia each at 3 percent. The hypoglycemic event...multicenter, randomized, double-blind, parallel-group study comparing...short-term use of ≤15 days. The primary endpoints of the...

Data on gene therapy published by J.R. Mendell and colleagues.
Gene Therapy Weekly; 11/19/2009; 790 words; ...expression. A double-blind, randomized controlled...received saline. A 3-day course of methylprednisolone...weeks (2 subjects) and 3 months (1 subject...was increased in the 3-month subject. Adeno...Division John Wiley & Sons Inc., 111 River St...

New findings from Appalachian State University in the area of inflammation published.(Report)
Biotech Week; 11/18/2009; 915 words; ...supplements under double-blind methods for 6 wk before and during a 3-d period in which they cycled for 3 hr/d at similar to...final 15 min of each 3-hr bout. Blood and...exercise bout on the third day, and 14 hr postexercise...Human Kinetics Publ Inc., 1607 N Market St...

Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX[R] Varenicline Compared With Placebo.
Vaccine Weekly; 11/18/2009; 2451 words; ...results showed that 42.3 percent of smokers...see also Pfizer Inc). "Quitting smoking...them are smokers.3,4 Further, approximately...multicenter, double-blind, placebo-controlled...cigarettes or more per day in the year before...weeks 9-12), 42.3 percent of study participants...

Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid Dependence.
Business Wire; 11/16/2009; 2317 words; ...Mass. -- Alkermes, Inc. (NASDAQ: ALKS...results from a phase 3 clinical trial of naltrexone...Study Design The phase 3 randomized, multi...a minimum of seven days prior to treatment...24-week double-blind treatment period...endpoints in the phase 3 study were the study...